The Latest Breaking News from Novo Nordisk

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

Novo Nordisk will report first-quarter earnings on May 4.

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes.  Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Novo Nordisk A/S (NYSE: NVO) 

  Novo Nordisk (NYSE:NVO) reported its Q4 earnings results on Wednesday, February 2, 2022 at 01:30 AM. Here's what investors need to know about the announcement.